Kisspeptin for Ovulation Induction in Hypothalamic Amenorrhea
Kisspeptin is currently experimental and not clinically available for ovulation induction in women with hypothalamic amenorrhea; use pulsatile GnRH as first-line treatment (if available), followed by gonadotropins with both FSH and LH activity. 1
Experimental Kisspeptin Dosing Protocols
While kisspeptin shows promise in research settings, the 2017 Endocrine Society guidelines explicitly state that kisspeptin is not yet clinically available and requires more research before therapeutic use 1. The experimental protocols studied include:
Continuous Infusion Protocol (Most Promising)
- Kisspeptin-54 via continuous IV infusion for 10 hours at variable doses successfully increased LH pulsatility in all five women with FHA without desensitization 1
- Dose range: 0.01 to 1.00 nmol/kg/h, with peak responses varying by individual patient 2
- This approach demonstrated a 3-fold increase in LH pulses and 6-fold increase in LH pulse secretory mass compared to placebo 2
Failed Protocols (Avoid These)
- Twice-daily subcutaneous injections: Caused rapid tachyphylaxis with LH responsiveness diminishing gradually and FSH responsiveness nearly abolished by day 2 3
- Twice-weekly subcutaneous injections: Resulted in only partial desensitization but still insufficient for sustained ovulation induction 4
Novel Intranasal Route (Emerging)
Recent 2025 data shows intranasal kisspeptin-54 at 12.8 nmol/kg rapidly stimulates gonadotropins in women with hypothalamic amenorrhea (mean maximal LH increase of 4.4 ± 0.2 IU/L) without adverse effects 5. However, this remains investigational.
Recommended Alternative Treatments (In Order of Preference)
First-Line: Pulsatile GnRH
Use pulsatile GnRH as first-line therapy when available 1:
- Ovulation rate: 75% with highest rates in primary hypogonadotropic amenorrhea 1
- Pregnancy rate: 29% per cycle in women without other infertility factors 1
- Cumulative conception rate: 96% after 6 cycles 1
- Multiple pregnancy rate: Only 3.8-8.3% (significantly lower than gonadotropins) 1
- Maintains physiologic pituitary-ovarian feedback with monofollicular development 1
Critical limitation: GnRH is currently unavailable in the United States 1
Second-Line: Gonadotropin Therapy
When GnRH is unavailable, use gonadotropins cautiously, ensuring both FSH and LH activity 1:
- Use human menopausal gonadotropin (hMG) or combination FSH/LH preparations
- Avoid recombinant FSH alone - women with FHA require LH activity for optimal response 1
- Cumulative conception rate: 72% after 6 cycles 1
- Higher risk: 16.6% develop ≥3 follicles; 14.8% multiple gestation rate 1
Third-Line: Clomiphene Citrate
Consider clomiphene only if sufficient endogenous estrogen is present 1:
- Standard 5-day regimens typically fail in FHA 1
- Prolonged protocol may work: 50 mg/day for 5 days, then 100 mg/day for 5 days, starting day 3 after withdrawal bleeding 6
- In one small series, 6/8 women responded to first cycle; remaining 2 responded to second cycle 6
- Limited evidence base with no randomized trials 1
Adjunctive: Cognitive Behavioral Therapy
A 20-week randomized trial showed CBT leads to recovery of ovulation AND improves metabolic function in normal-weight women with FHA 1. Consider this alongside fertility treatments.
Critical Prerequisites Before Ovulation Induction
Only induce ovulation when BMI ≥18.5 kg/m² and after attempts to normalize energy balance 1:
- BMI <18.5 kg/m² increases risk of:
Common Pitfalls to Avoid
- Using recombinant FSH without LH activity - leads to inadequate estradiol response in women with FHA 1
- Attempting ovulation induction in underweight women - significantly increases adverse pregnancy outcomes 1
- Standard clomiphene protocols - unlikely to work as FHA patients cannot respond to estrogen negative feedback loop opening 1
- Pursuing kisspeptin therapy - not clinically available despite promising research 1